Filgrastim

證據等級: L5

預測適應症: 10 個

Filgrastim: From Neutropenia to Primary Release Disorder of Platelets

One-Sentence Summary

Filgrastim is a recombinant human Granulocyte Colony-Stimulating Factor (G-CSF), primarily used clinically to treat chemotherapy-induced neutropenia and to mobilize hematopoietic stem cells for transplantation. The TxGNN model predicts it may be effective for Primary Release Disorder of Platelets, with 14 clinical trials and 1 publication identified in the evidence search — however, none of the trials directly target this indication, and the evidence is largely indirect. Given the weak mechanistic link and absence of direct clinical data, the current recommendation is Hold pending further mechanistic validation.

Quick Overview

Item	Content
Original Indication	Neutropenia treatment and hematopoietic stem cell mobilization (known pharmacology; no Philippines registration data available)
Predicted New Indication	Primary Release Disorder of Platelets
TxGNN Prediction Score	99.998%
Evidence Level	L4
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacology, Filgrastim is a recombinant G-CSF that primarily stimulates the proliferation and differentiation of neutrophil precursors in the bone marrow, accelerating neutrophil recovery following myelosuppressive chemotherapy. It also plays a well-established role in mobilizing CD34+ hematopoietic stem and progenitor cells into the peripheral blood for collection and transplantation.

The predicted connection to primary release disorder of platelets rests on an indirect theoretical pathway: G-CSF receptors (G-CSFR/CD114) are expressed on megakaryocytes — the precursor cells that give rise to platelets — and stimulation of this receptor may theoretically influence megakaryocyte maturation and, consequently, platelet granule biosynthesis. Primary release disorder of platelets involves defects in dense granule (δ-granule) or alpha-granule (α-granule) secretion, impairing platelet activation upon vascular injury. In principle, if G-CSF can influence the granule content during megakaryopoiesis, it might partially compensate for these secretion defects.

However, this mechanistic hypothesis is highly speculative. The repurposing rationale explicitly notes that G-CSF has no established direct mechanism on platelet granule release function. The high TxGNN prediction score most likely reflects the graph-structural proximity between G-CSF nodes and platelet-related disease nodes in the knowledge graph, rather than true pharmacological relevance. No preclinical studies have yet validated this pathway, making this a model-generated hypothesis requiring experimental confirmation before any clinical translation is considered.

Clinical Trial Evidence

The following trials were identified in the evidence search. All retrieved trials involve Filgrastim in the context of stem cell mobilization or supportive care for hematologic malignancies — none directly study Filgrastim for primary release disorder of platelets.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04047628	Phase 3	Recruiting	156	RCT comparing autologous HSCT vs. best available therapy in treatment-resistant relapsing MS; Filgrastim used for stem cell mobilization. Highest-quality trial identified, but not directly relevant to platelet release disorders.
NCT00245037	Phase 1/2	Completed	147	Non-myeloablative allogeneic HSCT using busulfan/fludarabine/TBI for hematologic malignancies; Filgrastim as mobilization agent.
NCT00043979	Phase 2	Completed	60	Allogeneic/syngeneic blood stem cell transplantation for high-risk pediatric sarcomas; Filgrastim for stem cell mobilization.
NCT01335932	Phase 2	Completed	160	RCT of ganciclovir to prevent CMV reactivation in sepsis/trauma-associated respiratory failure; Filgrastim as background supportive therapy.
NCT01503918	Phase 2	Completed	124	Antiviral prophylaxis for CMV reactivation in ICU patients; Filgrastim as supportive care.
NCT00923364	Phase 2	Completed	19	Reduced-intensity HSCT for patients with GATA2 mutations; Filgrastim for stem cell mobilization.
NCT00076752	Phase 2	Completed	9	Intensified lymphodepletion followed by autologous HSCT for severe SLE; Filgrastim for stem cell mobilization.
NCT02646098	Phase 2	Completed	64	CD34+ selection vs. unselected autologous SCT in mantle cell and diffuse large B-cell lymphoma.
NCT05436418	Phase 1/2	Recruiting	260	Post-transplant cyclophosphamide-based GVHD prophylaxis after reduced-intensity conditioning and PBSCT.
NCT06859424	Phase 2	Recruiting	358	Platform protocol investigating PTCy-based GVHD prophylaxis after mismatched unrelated donor PBSCT.

⚠️ Note: None of these trials are designed to evaluate Filgrastim as a therapeutic agent for primary release disorder of platelets. Filgrastim appears exclusively as a stem cell mobilization or supportive care agent. These trials do not constitute clinical evidence for the predicted indication.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29770133	2018	Clinical/Observational	Frontiers in Immunology	G-CSF-based peripheral blood stem cell mobilization in healthy allogeneic donors preferentially mobilizes specific lymphocyte subsets; discusses immune modulation potential of G-CSF. Not directly relevant to platelet release disorders.

Philippines Market Information

Filgrastim is currently not registered with the Food and Drug Administration of the Philippines (FDA-Philippines). No marketing authorizations have been identified.

Authorization Number	Product Name	Dosage Form	Approved Indication
—	No registrations found	—	—

Safety Considerations

Formal safety data (warnings and contraindications from the Philippines package insert) is not available in this Evidence Pack.

Please refer to the package insert for standard safety information.

Nonetheless, mechanistic analysis of the predicted indication landscape has identified the following indication-specific safety signals that warrant attention if any clinical exploration is considered:

Pseudo-von Willebrand Disease (Rank 2 prediction): G-CSF has been reported to increase circulating von Willebrand Factor (vWF) concentrations via endothelial cell activation. This could theoretically exacerbate pseudo-vWD symptoms (GPIbα gain-of-function mutations causing excess platelet-vWF binding), representing a potential safety hazard rather than a therapeutic benefit.
C1 Inhibitor Deficiency / Hereditary Angioedema (Rank 7 prediction): G-CSF causes large-scale neutrophil mobilization that may activate the contact activation system (Factor XII), potentially accelerating bradykinin generation. Case reports of G-CSF-induced HAE-like episodes exist in the literature. This indication carries a potential harm signal and should not be pursued.
Serpinopathy with Toxic Serpin Polymerization (Rank 8 prediction): G-CSF increases neutrophil elastase secretion, while serpins (e.g., alpha-1 antitrypsin) are physiologically designed to inhibit this enzyme. Administration of G-CSF in serpin-deficient states may theoretically accelerate tissue damage (e.g., pulmonary emphysema progression).

Conclusion and Next Steps

Decision: Hold

Rationale: All 14 clinical trials retrieved involve Filgrastim exclusively as a stem cell mobilization or supportive care agent in hematologic malignancy contexts; none provide direct therapeutic evidence for primary release disorder of platelets, and the mechanistic hypothesis linking G-CSF to platelet granule secretion is indirect and unvalidated. Furthermore, several of the co-predicted indications carry active safety concerns, suggesting that broad exploration in platelet-related disorders requires careful pre-screening.

To proceed, the following is needed:

MOA validation: Retrieve full mechanism of action data from DrugBank API (DG002) to confirm whether G-CSF receptor expression on megakaryocytes is sufficient to justify further investigation.
Preclinical evidence: In vitro or animal studies specifically evaluating G-CSF effects on platelet dense granule or alpha-granule secretion are required before any clinical hypothesis can be formed.
Philippines regulatory data: Download and parse the Philippines FDA package insert PDF to obtain local warnings and contraindications (DG001), which is currently a blocking data gap.
Safety differentiation: Conduct a systematic safety analysis to distinguish which platelet disorder subtypes might be safe to study (e.g., constitutional thrombocytopenia where G-CSF’s megakaryocyte-stimulating effect is theoretically plausible) from those where G-CSF may be harmful (pseudo-vWD, C1 inhibitor deficiency).
Literature deep dive: Commission a targeted PubMed/EMBASE search combining G-CSF with megakaryocyte function, platelet granule, and dense granule release to identify any unpublished or niche mechanistic studies not captured in this initial evidence pull.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.